Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20518706 | 0.78 | GAA (0.40) | GAAALDH1A1CYP1A2RECQLTDP1 | |
| SCHEMBL20518699 | 0.78 | GAA (0.40) | GAAALDH1A1CYP1A2RECQLTDP1 | |
| SCHEMBL18839734 | 0.72 | GAA (0.41) | GAAALDH1A1CYP1A2RECQLTDP1 | |
| SCHEMBL18839580 | 0.70 | GAA (0.59) | GAAALDH1A1CYP1A2RECQLTDP1 | |
| SCHEMBL20518651 | 0.70 | ALDH1A1 (0.31) | ALDH1A1RECQLHCRTR1HCRTR2 | |
| SCHEMBL18839677 | 0.66 | GAA (0.50) | GAAALDH1A1CYP1A2RECQLTDP1 | |
| SCHEMBL18839796 | 0.66 | GAA (0.53) | GAAALDH1A1CYP1A2RECQLTDP1 | |
| SCHEMBL22326350 | 0.64 | GAA (0.88) | GAAALDH1A1CYP1A2RECQLTDP1 | |
| SCHEMBL15292529 | 0.64 | GAA (0.62) | GAAALDH1A1CYP1A2RECQLTDP1 | |
| SCHEMBL18839742 | 0.63 | SMN1; SMN2 (0.53) | GAAALDH1A1CYP1A2RECQLTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180282331-A1 | 7-Oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections (changed by PCT to: 7-OXO -6-(SULFOOXY)- 1,6-DIAZABICYCLO [3.2.1] OCTANE CONTAINING COMPOUNDS AND THEIR USE IN TREATMENT OF BACTERIAL INFECTIONS | WOCKHARDT LIMITED (IN) | 2018-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282331-A1 | 7-Oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections (changed by PCT to: 7-OXO -6-(SULFOOXY)- 1,6-DIAZABICYCLO [3.2.1] OCTANE CONTAINING COMPOUNDS AND THEIR USE IN TREATMENT OF BACTERIAL INFECTIONS | TST, THPO, STS | GAA 4163/4885ALDH1A1 2258/4885CYP1A2 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.